A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy

Trial Profile

A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Peripheral neuropathies
  • Focus Biomarker; Therapeutic Use
  • Sponsors Spinifex Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2015 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
    • 11 Apr 2014 Trial is ongoing, as reported in a Spinifex Pharmaceuticals media release.
    • 11 Dec 2012 Planned number of patients changed from 40 to 50, as reported in a Spinifex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top